GlassScriptPhysician profile
Ahmet Dervish
NPI 1104854462
$1,379.69
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $812 · 2021: $18.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $773.21 | 2020 | |
| Pacira Therapeutics, INC. | $299.97 | 2019-2020 | |
| Depuy Synthes Sales INC. | $81.72 | 2019 | |
| Allergan, INC. | $44.74 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.15 | 2019 | |
| Electronic Waveform Lab, INC. | $27.00 | 2019-2020 | |
| Amgen INC. | $25.14 | 2019 | |
| Shionogi INC | $22.45 | 2019 | |
| Pfizer INC. | $15.10 | 2019 | |
| Biodelivery Sciences International, INC. | $14.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.40 | 2019 | |
| Lilly USA, LLC | $13.34 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmet Dervish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.